Evidence map›Paper›PMID 40598530›Full record

ArticleCell communication and signaling : CCS2025

Hormonally upregulated neu tumor-associated kinase (HUNK) modulates gastric cancer progression through the regulation of cell homeostasis.

Giuseppina di Paola, Francesco Albano, Pietro Zoppoli, Daniele Bravoco, Teresa D'Amore, Elena Amendola, Valeria Lucci, Luca Roberto, Mariarita Brancaccio, Paolo Salerno and 8 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Giuseppina di Paola *Biogem scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Avellino, 83031, Italy.
Francesco Albano *Department of Biology, University of Naples Federico II, Naples, 80147, Italy.
Pietro ZoppoliDepartment of Molecular Medicine and Health Biotechnology, University di Napoli Federico II, Naples, 80131, Italy.
Daniele BravocoBiogem scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Avellino, 83031, Italy.
Teresa D'AmoreIRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy.
Elena AmendolaDepartment of Biology, University of Naples Federico II, Naples, 80147, Italy.
Valeria LucciDepartment of Biology, University of Naples Federico II, Naples, 80147, Italy.
Luca RobertoBiogem scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Avellino, 83031, Italy.
Mariarita BrancaccioDepartment of Biology, University of Naples Federico II, Naples, 80147, Italy.
Paolo SalernoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, 80138, Italy.
Giovanni CaliceIRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy.
Simona LaurinoIRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy.
Sabino RussiIRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, Italy.
Cristofaro De StefanoU.O.C Reproduction Physiology Unit, San Giuseppe Moscati, Avellino, 83100, Italy.
Monica MaielloU.O.C Reproduction Physiology Unit, San Giuseppe Moscati, Avellino, 83100, Italy.
Giuseppe MerlaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, 80138, Italy.
Geppino Falco *Biogem scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Avellino, 83031, Italy. geppino.falco@unina.it.
Pellegrino Mazzone *Biogem scarl, Istituto di Ricerche Genetiche 'Gaetano Salvatore', Ariano Irpino, Avellino, 83031, Italy. pellegrino.mazzone@biogem.it.

Funding

National Center for Gene Therapy and Drugs based on RNA Technology" financed by EU-NextGenerationEU CN00000041PRIN PNRR 2022 P2022TJ948
6 · The paper itself

Abstract

Gastric cancer (GC) is a neoplasia with an increase in incidence and mortality over the next years. Currently, the treatment of this malignancy consists of surgery in association with the administration of platinum compounds or 5-FU capecitabine. The identification of novel biomarkers related to the GC progression is a key point in re-modulating the pharmacological treatment to get a more efficient patient response. In this study, we reported that Hormonally Upregulated Neu tumor-associated Kinase (HUNK) promotes gastric cancer progression by regulating cell homeostasis. Particularly, we demonstrated that HUNK is responsible for the increase in gastric cancer cell proliferation through the binding and phosphorylation of p38 MAP kinase and that its depletion is associated with a reduction of survival both in gastric cancer cells and patient-derived organoids. Further, we reported that HUNK regulates positively the expression of MUC16/CA-125, a well-known cancer prognostic marker. Our findings shed light, for the first time, on the molecular mechanisms regulated by HUNK in gastric cancer cells making this kinase a promising candidate for novel targeted therapeutic strategies.

Indexed as

Disease ProgressionHomeostasisStomach NeoplasmsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansp38 Mitogen-Activated Protein KinasesPhosphorylationUp-Regulationp38 Mitogen-Activated Protein Kinases

Identifiers

PMID40598530
PMCPMC12218837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.